The challenge of new drug discovery for tuberculosis

By A. Koul, E. Arnoult, N. Lounis, J. Guillemont, K. Andries. Nature, 2011

1,048 citations recorded by the source corpus.

Subfields: Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e2a9b79ff5be87e3b0381fc2869a3d1f7a7b4f58

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. M. Gengenbacher
2. Stefan H. E. Kaufmann

In Molecular Biology

1. M. Gengenbacher
2. Stefan H. E. Kaufmann
3. Linlin Wang
4. Chen Hu
5. L. Shao

Citations in the corpus

• The antimicrobial activity of nanoparticles: present situation and prospects for the future (2017, methodology): “Therefore, in the pre-NP era, three methods used to overcome antibiotic resistance were the development of new drugs, high-dose administration of an antibiotic,(6) and the combination of multiple antibiotics.(30,31) However, the production of novel antibiotics could not keep up with the mutation of ”
• Mycobacterium tuberculosis: Success through dormancy (2012, background): “The etiology of tuberculosis (TB) – one of the most devastating diseases of humankind – was first elucidated by Robert Koch (1843–1910) in 1882 (Koch, 1882, 1932; Kaufmann & Winau, 2005).”